Abstract:Meriem Chayah, 1– 3 Angélica Luque-González, 1 Verónica Gómez-Pérez, 1 Diego Salagre, 4, 5 Amjad Al-Shdaifat, 6 Joaquín María Campos, 1, 2 Ana Conejo-García, 1, 2 Ahmad Agil 2, 4, 5 1 Department of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, University of Granada, Granada, Spain; 2 Biosanitary Institute of Granada (Ibs.granada), SAS-University of Granada, Granada, Spain; 3 Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government (GENYO), Granada, Spain; 4 Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; 5 Federico Oloriz Neuroscience Institute, University of Granada, Granada, Spain; 6 Department of Medicine and Family Medicine, Faculty of Medicine, Hashemite University, Zarqa, Jordania Correspondence: Ahmad Agil; Ana Conejo-García, Email ; Type 2 diabetes mellitus (T2DM) is one of the world's principal metabolic diseases characterized by chronic hyperglycemia. The gut incretin hormones, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), which has been proposed as a new treatment for T2DM, are extensively metabolized by Dipeptidyl peptidase 4 (DPP-4). Inhibitors of DPP-4 block the degradation of GLP-1 and GIP and may increase their natural circulating levels, favoring glycemic control in T2DM. A novel and potent selective inhibitor of DPP-4 with an 8-purine derived structure ( 1 ) has been developed and tested in vitro and in vivo in Zücker obese diabetic fatty (ZDF) rats, an experimental model of the metabolic syndrome and T2DM to assess the inhibitory activity using vildagliptin as reference standard. ZDF rats were subdivided into three groups (n = 7/group), control (C-ZDF), and those treated with compound 1 (Compound 1 -ZDF) and with vildagliptin (V-ZDF), both at 10 mg/kg/d rat body weight, in their drinking water for 12 weeks, and a group of lean littermates (ZL) was used. ZDF rats developed DM (fasting hyperglycemia, 425 ± 14.8 mg/dL; chronic hyperglycemia, HbA1c 8.5 ± 0.4%), compared to ZL rats. Compound 1 and vildagliptin reduced sustained HbAl1c (14% and 10.6%, P < 0.05, respectively) and fasting hyperglycemia values (24% and 19%, P < 0.05, respectively) compared to C-ZDF group (P < 0.001). Compound 1 and vildagliptin have shown a potent activity with an IC 50 value of 4.92 and 3.21 μM, respectively. These data demonstrate that oral compound 1 administration improves diabetes in ZDF rats by the inhibitory effect on DPP-4, and the potential to be a novel, efficient and tolerable approach for treating diabetes of obesity-related T2DM, in ZDF rats. Keywords: diabetes mellitus type 2, DPP-4 inhibitors, purine derivatives, ZDF rats Diabetes is a major global problem nowadays. It currently affects nearly 537 million people worldwide in 2023, and this number will rise to 700 million in 2045. 1 Among the latest approaches for the treatment of T2DM, the inhibition of the enzyme DPP-4 emerged as an interesting alternative. This approach is based on the key role that DPP-4 has in the inactivation of the two primary endogenous incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), both secreted from the intestine to stimulate insulin secretion from pancreatic β cells. 2 The incretin effect accounts for at least 50% of the total insulin secreted after ingestion. In addition to its insulinotropic effects, GLP-1 decreases food intake, inhibits glucagon secretion and gastric emptying, and slows the rate of endogenous glucose production. 3 It has also been shown to stimulate β-cell proliferation and to protect them from apoptosis. Both peptides had sparked interest in their therapeutic potential as anti-diabetic agents. However, they are rapidly inactivated by DPP-4 resulting in a half-life of only 1–2 minutes. 4 Therefore, the inhibition of DPP-4 prolongs the half-life and increases the levels of endogenous active GLP-1 and thereby greatly enhances its insulinotropic effect. 5 Currently, DPP-4 inhibitors are firmly established as a treatment for T2DM proving efficacy and better glycemic control leading to a statistically significant long-term reduction in glycated hemoglobin (HbA1c) without risk of hypoglycemia and cardiovascular side effects. 6,7 Thus, several DPP-4 inhibitors, such as vildagliptin, saxagliptin, sitagliptin, alogliptin, or linagliptin (Figure 1), are approved worldwide as monotherapy o -Abstract Truncated-

213-OR: Antidiabetic Potential of Novel, Long-Acting Amylin Analogue ZP8396 in ZDF Rats

788-P: Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models

116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice

1961-P: Improved Glucose Control and Robust Weight Loss with a Long-Acting OXM-001

Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.

Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats

297-OR: A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis

PGLP-1, a Novel Long-Acting Dual-Function GLP-1 Analog, Ameliorates Streptozotocin-Induced Hyperglycemia and Inhibits Body Weight Loss.

Amg 837: A Novel Gpr40/Ffa1 Agonist That Enhances Insulin Secretion And Lowers Glucose Levels In Rodents

Evaluating the effectiveness of a novel somatostatin receptor 2 antagonist, ZT-01, for hypoglycemia prevention in a rodent model of type 2 diabetes

Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist

The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes

Pharmacological Effects of EGLP-1, a Novel Analog of Glucagon-Like Peptide-1, on Carbohydrate and Lipid Metabolism

Dose–response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

Results of an Interim Analysis of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of ZGN-1061 in Patients with Obesity and Type 2 Diabetes

2059-LB: NA-931, a Novel Triple IGF-1/GLP-1/GIP Incretin Receptor Agonist Reduces Body Weight and Improves Metabolic Profile in DIO Mice

Hypoglycemic Efficacy of Rh-aFGF Variants in Treatment of Diabetes in ZDF Rats

A Novel Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist Exhibits Weight-Lowering and Diabetes-Protective Effects.

789-P: Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control

Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long‐acting dual amylin and calcitonin receptor agonist improves insulin‐mediated glycaemic control and controls body weight

Design of a Novel Long-Acting Dual GLP-1/GIP Receptor Agonist